(New York, NY – August 29, 2018) — Mount Sinai researchers have discovered that a particular type of cell present in bladder cancer may be the reason why so many patients do not respond to the groundbreaking class of drugs known as PD-1 and PD-L1 immune checkpoint inhibitors, which enable the immune system to attack tumors.
In a study published in August in Nature Communications, the Mount Sinai team reported that stromal cells, a subset of connective tissue cells often found in the tumor environment, may be preventing immune cells known as T-cells from seeking out and destroying the invading cancer. The researchers showed that expression of a set of genes that are typically linked to more aggressive cancers was actually more commonly linked to stromal cells rather than bladder cancer cells themselves. They also showed that tumors with increased expression of these genes, known as epithelial mesenchymal transition genes, did not respond well to immune checkpoint inhibitors. The researchers also found that in such tumors, T-cells were more likely to be separated from cancer cells by the stromal cells, suggesting that the stromal cells may be hindering the ability of the immune cells to reach and eradicate the
Article originally posted at